SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation Q192R

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials


1 Paraoxonase and LDL Oxidation in Carotid Artery Disease

Atherosclerosis of the carotid arteries is a common cause of stroke. The prevalence and progression of carotid atherosclerosis are believed to be influenced by genetically inherited variations in lipoprotein metabolism. This study investigates the specific role of paraoxonase, an enzyme thought to detoxify atherogenic oxidized low-density lipoprotein. This study compares veterans who have significant carotid atherosclerosis on ultrasound examination with controls without carotid atherosclerosis. Both paraoxonase activity and genotype will be determined and compared between groups. The results may eventually make it possible to screen for a paraoxonase allele that confers high risk of atherosclerosis, and to diminish the risk by early treatment.

NCT00011258 Carotid Stenosis Drug: Paraoxonase
MeSH:Carotid Stenosis Carotid Artery Diseases
HPO:Carotid artery stenosis

Two paraoxonase (PON1) polymorphisms, PON1-Q192R and PON1-L55M have been inconsistently associated with vascular disease. --- Q192R ---


2 Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients

This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.

NCT02707445 Myocardial Ischemia CLOPIDOGREL, POOR METABOLISM of (Disorder) Drug: Clopidogrel
MeSH:Myocardial Ischemia Ischemia
HPO:Myocardial infarction

Genes which are known to be related with clopidogrel resistance were evaluated; (1-3) CYP 2C19 *2, *3, *17, (4) PON1 Q192R, (5) ABCB1 3435C->T, (6) P2Y12, (7) CYP 2C9 *3. --- Q192R ---

Primary Outcomes

Measure: Myocardial infarction and Death

Time: 1 year after index procedure

Secondary Outcomes

Measure: Any death

Time: 1 year after index procedure

Measure: Cardiac death

Time: 1 year after index procedure

Measure: Myocardial infarction

Time: 1 year after index procedure

Measure: Stent thrombosis (acute, late, very late)

Time: 1 year after index procedure

Description: Revascularization of in-stent restenosis which developed in previously implanted stent on index procedure

Measure: Target lesion revascularization

Time: 1 year after index procedure

Description: Ischemic or hemorrhagic cerebral infarction diagnosed by brain MRI which developed within 1 year after index procedure

Measure: Stroke

Time: 1 year after index procedure

Measure: Bleeding complication

Time: During index procedure

Description: Value which is measured with VerifyNow that can monitor platelet inhibition of clopidogrel

Measure: PRU

Time: Within index procedure

Description: Value which is measured with VerifyNow that can monitor platelet inhibition of aspirin

Measure: ARU

Time: Within index procedure


HPO Nodes